Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Expression of the anthracycline-metabolizing enzyme carbonyl reductase 1 in hearts from donors with Down syndrome.

Drug metabolism and disposition: the biological fate of chemicals - 1 Dec 2010

Kalabus James L, Sanborn Carrie C, Jamil Raqeeb G, Cheng Qiuying, Blanco Javier G

Abstract excerpt

Cancer patients with Down syndrome (DS) are susceptible to developing anthracycline-related cardiotoxicity. The pathogenesis of anthracycline-related cardiotoxicity has been linked to the intracardiac synthesis of alcohol metabolites by carbonyl reductase 1 (CBR1). CBR1 is located in the DS critical region (21q22.12). The expression of CBR1 in hearts from individuals with DS has not been characterized. This study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcohol Oxidoreductases
Share to Anthracyclines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Down Syndrome

Share to Genotype

Share to Myocardium

Share to RNA, Messenger

Share to Tissue Donors

Source

Open in PubMed Open full text

Identifiers

PMID: 20729274
DOI: 10.1124/dmd.110.035550
PMCID: PMC2993452

Genes

CBR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Expression of the anthracycline-metabolizing enzyme carbonyl reductase 1 in hearts from donors with Down syndrome.PMID 20729274Read ↗

Interindividual variability in the cardiac expression of anthracycline reductases in donors with and without Down syndrome.Semantic proximity Read ↗

Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors.Semantic proximity Read ↗

Post-daunorubicin treatment effects on cardiovascular function in the Ts65Dn mouse model of Down syndromeSemantic proximity Read ↗

Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1.Semantic proximity Read ↗

Risk factors for anthracycline-associated cardiotoxicity.Semantic proximity Read ↗

A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity.Semantic proximity Read ↗

Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.Semantic proximity Read ↗

Functional Validation of Doxorubicin-Induced Cardiotoxicity-Related GenesSemantic proximity Read ↗

Human carbonyl reductase (CBR) localized to band 21q22.1 by high-resolution fluorescence in situ hybridization displays gene dosage effects in trisomy 21 cells.Semantic proximity Read ↗

Carbonyl Reductase 1: a novel regulator of blood pressure in Down SyndromeSemantic proximity Read ↗

NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced CardiotoxicitySemantic proximity Read ↗

A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.